Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
JTO Clinical and Research Reports|June 19, 2025
Erratum to 'Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796]Mariona Riudavets, David PlanchardCancer Research and Treatment|November 28, 2024
The Era of Antibody Drug Conjugates in Lung Cancer: Trick or Threat?Mariona Riudavets, David PlanchardExpert Opinion on Pharmacotherapy|December 21, 2022
An update on lorlatinib: a novel first line treatment for ALK-positive advanced lung cancerMariona Riudavets, David PlanchardLung Cancer (Amsterdam, Netherlands)|June 13, 2022
Targeting BRAF-mutant non-small cell lung cancer: Current status and future directionsMariona Riudavets, Priscilla Cascetta, David PlanchardCancers|July 9, 2022
Radon and Lung Cancer: Current Trends and Future PerspectivesMariona Riudavets, Marta Garcia de Herreros, Benjamin Besse, et al.Bulletin Du Cancer|March 28, 2025
[Treatment with peri-operative immunotherapy of resectable PCNBs]Mariona Riudavets, Gary Birsen, Jeremy Slomka, et al.Personalized Medicine|June 24, 2022
Targeting molecular alterations in non-small-cell lung cancer: what's next?Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, et al.JTO Clinical and Research Reports|December 6, 2022
Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case ReportMariona Riudavets, Arshid Azarine, Sondes Smaali, et al.JTO Clinical and Research Reports|May 2, 2022
Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case ReportMariona Riudavets, Benjamin Wyplosz, Maria Rosa Ghigna, et al.Cancers|May 11, 2024
Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 InhibitorsLeticia Alserawan, Maria Mulet, Geòrgia Anguera, et al.Pageof 3